Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | JZP-458 |
Synonyms | |
Therapy Description |
JZP-458 is a recombinant asparaginase derived from the Erwinia chrysanthemi bacterium, which converts L-asparagine to L-aspartic acid and ammonia resulting in decreased L-asparagine levels, leading to inhibition of protein synthesis and potentially decreasing tumor cell proliferation (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JZP-458 | JZP458|JZP 458|RC-P JZP-458|crisantaspase biobetter JZP-458 | JZP-458 is a recombinant asparaginase derived from the Erwinia chrysanthemi bacterium, which converts L-asparagine to L-aspartic acid and ammonia resulting in decreased L-asparagine levels, leading to inhibition of protein synthesis and potentially decreasing tumor cell proliferation (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04145531 | Phase II | JZP-458 | An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) | Completed | USA | CAN | 0 |